Cochlear Ltd (ASX: COH) shares are enjoying an impressive rebound.
The ASX healthcare stock rose another 2% to start the week, extending its gain over the past month to 23%.
Even so, the recovery only tells part of the story. Cochlear shares remain down around 54% in 2026 and roughly 60% over the past 12 months.
So, what triggered such a dramatic collapse? And after the recent bounce, where do brokers think the shares are headed next?
Image source: Getty Images
What went wrong?
To understand the recent recovery, it's worth revisiting what happened in April. On 22 April, Cochlear stunned investors with a trading update that triggered one of the biggest one-day sell-offs on the ASX this year.
The company reported weaker-than-expected demand for its hearing implants across developed markets. It also cited cancellations and shipment delays in the Middle East due to ongoing regional conflict.
The market reacted swiftly. Cochlear shares plunged more than 40% in a single trading session as investors reassessed the company's growth outlook. Management also slashed its FY26 underlying net profit guidance to between $290 million and $330 million, down sharply from its previous forecast of $435 million to $460 million.
Since then, the key question has been whether this was a temporary setback or the start of a more prolonged slowdown.
Has the investment case changed?
Despite the earnings downgrade, many of Cochlear's long-term strengths remain intact. The company still commands around half of the global cochlear implant market, making it the clear industry leader.
That position has been built over decades of research, product development, and close relationships with healthcare providers worldwide. Its products are deeply embedded in healthcare systems, creating significant barriers for competitors trying to gain market share.
The long-term growth opportunity for Cochlear shares also remains compelling. The addressable market is estimated to exceed six million patients across developed markets, yet only around 3% of eligible patients currently receive cochlear implants.
That leaves enormous scope for future growth as diagnosis rates improve, awareness increases, and technology continues to advance. An ageing global population should provide another powerful tailwind over the coming decades.
What do brokers think?
Analysts remain cautious, but few appear ready to abandon the stock. According to TradingView data, most brokers currently rate Cochlear shares as a hold. The average 12-month price target sits at $129.12, implying approximately 7% upside from current levels.
Among them is Bell Potter, which continues to recommend holding the shares. The broker believes the company's long-term outlook remains attractive, citing its dominant market position, sizeable addressable market, and ongoing product innovation.
However, many analysts are waiting for stronger evidence that hearing implant volumes have stabilised before becoming more optimistic.
Buy, hold or sell?
For long-term investors, Cochlear still possesses many of the qualities that made it one of Australia's highest-quality healthcare companies. But after April's profit warning, confidence has been shaken.
The recent rebound of Cochlear shares suggests investors are beginning to look beyond the near-term challenges. Even so, broker forecasts indicate only modest upside over the next year.
For now, the consensus view appears clear: Cochlear's long-term story remains compelling, but investors may need more evidence of an operational recovery before the shares regain their former momentum.
